- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 29
- States / cities
- Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 56
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Prostatic Neoplasms
- Interventions
- ORIC-101, enzalutamide 40 MG oral capsule [Xtandi]
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- New York, New York • Myrtle Beach, South Carolina • Houston, Texas
- Conditions
- Metastatic Prostate Cancer
- Interventions
- ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 20
- States / cities
- Colorado Springs, Colorado • Plantation, Florida • Arlington Heights, Illinois + 17 more
- Conditions
- Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Interventions
- Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
- Conditions
- Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Tazemetostat, Abiraterone/prednisone, Enzalutamide
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Diego, California • Denver, Colorado • Port Saint Lucie, Florida + 12 more
- Conditions
- Prostate Cancer, Pharmacokinetics of Enzalutamide
- Interventions
- Enzalutamide tablet, Enzalutamide capsule
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 95
- States / cities
- Colorado Springs, Colorado • Lakewood, Colorado • Lone Tree, Colorado + 57 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Atezolizumab, Enzalutamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 39
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Castration-Resistant Prostate Cancer
- Interventions
- Enzalutamide or Abiraterone or Apalutamid
- Combination Product
- Lead sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Port Jefferson Station, New York • Charlottesville, Virginia
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- enzalutamide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
- Interventions
- Enzalutamide, Abiraterone Acetate, Prednisone, Leuprolide Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Interventions
- PRL-02 injection, prednisone, dexamethasone, enzalutamide
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, Active Surveillance
- Drug · Other
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 41 more
- Conditions
- Castration Resistant Metastatic Prostate Cancer
- Interventions
- Testosterone cypionate, Enzalutamide, Testosterone enanthate
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 6
- States / cities
- San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Neoplasms
- Interventions
- GSK2636771, Enzalutamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Breast Cancer
- Interventions
- Enzalutamide, Placebo, Paclitaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 6
- States / cities
- Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more
- Conditions
- Breast Cancer
- Interventions
- Enzalutamide, exemestane, Placebo (for enzalutamide)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 89
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
- Interventions
- VERU-111, Enzalutamide, Abiraterone
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide Liquid, Enzalutamide Capsule
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
- Interventions
- PF-06952229, Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone, Enzalutamide
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more